fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18   |   19   |   20      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2009-12-13 Alopexx Pharmaceuticals (USA)
Sanofi-Aventis (France)
undisclosed human monoclonal antibody

The target of the antibody is a carbohydrate on the bacterial capsule known as PNAG which has been found to be a critical factor in the virulence and immune response to staphylococcal infections. / hospital-acquired and resistant infections
licensing
development
other
See details
2009-12-11 Intercell (Austria)
GSK Biologicals (UK)
needle-free, patch-based vaccines / travelers' diarrhea, pandemic influenza commercialization/ distribution
development
See details
2009-12-09 California Institute of Technology -Caltech (USA)
Sanofi-Aventis (France)
therapeutic and diagnostic solutions in human health R&D
other
See details
2009-12-09 Generex Biotechnology (USA)
Sanofi-Aventis (France)
recombinant human insulin crystals for Generex’s proprietary buccal insulin spray product, Generex Oral-lyn™ / diabetes manufacturing
See details
2009-12-08 Kurma Biofund (France)
Imperial Innovations (UK)
  other
See details
2009-12-08 CEVEC Pharmaceuticals (Germany)
Inno Biologics (Malaysia)
Human CAP® technology (stable producing human cell line from CEVEC)
licensing
manufacturing
See details
2009-12-08 Zymogenetics (USA)
Novo Nordisk (Denmark)
fully-human anti-IL21 monoclonal antibody (IL-21 mAb) / autoimmune and inflammatory diseases licensing
marketing/ promotion
See details
2009-12-03 ProMetic Biosciences (ProMetic Life Sciences' UK subsidiary)
undisclosed multinational company
undisclosed second-generation biopharmaceutical manufacturing
development
See details
2009-12-03 Targacept (USA)
AstraZeneca (UK)
TC-5214 (nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor subtypes)

/ major depressive disorder
R&D
licensing
commercialization/ distribution
development
marketing/ promotion
See details
2009-12-03 The Rockefeller University (USA)
Sanofi-Aventis
monoclonal antibody targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer’s disease / Alzheimer’s disease licensing
manufacturing
commercialization/ distribution
See details
2009-12-03 Rules-Based Medicine (USA)
Psynova Neurotech (UK)
Roche (Switzerland)
companion diagnostic / schizophrenia R&D
See details
2009-12-03 bioMérieux (France)
CEA (France)
new diagnostic technologies / infectious disease R&D
other
See details
2009-12-01 GATC Biotech (Germany)
Complete Genomics (USA)
  R&D
See details
2009-12-01 Protalix (Israel)
Pfizer (USA)
Uplyso® (taliglucerase alfa)
This enzyme replacement therapy is derived from a proprietary plant cell-based expression platform using genetically engineered carrot cells. / Gaucher's disease
commercialization/ distribution
development
See details
2009-11-25 Micromet (USA)
Lonza (Switzerland)
blinatumomab - MT103 (BiTE antibody for the treatment of various hematologic cancers) R&D
manufacturing
See details
[<<]      «      10   |   11   |   12   |   13   |   14   |   15   |   16   |   17   |   18   |   19   |   20      »      [65]